The North America Cardiovascular Digital Solutions Market would witness market growth of 3.6% CAGR during the forecast period (2022-2028).
Digital solutions have become a suitable accompaniment to traditional medicine due to their many advantages. These include simplicity of use, shortened development times, flexible delivery platforms, lower treatment costs, personalized treatment options, and improved medication adherence. The overall market is anticipated to increase consistently over time, given the advantages provided by these solutions and the increased desire for digital and remote solutions globally following the pandemic.
Ischemic heart disease, cardiomyopathies, cerebrovascular disease, arrhythmias, rheumatic heart disease, peripheral vascular disease, congenital heart disease, hypertensive heart disease, and other disorders are included in the broad category of CVD. Although non-modifiable factors (such as genetics, age, and sex) are equally significant, most CVD is hastened by mainly metabolic risk factors and modifiable behavioral. The majority of available scientific data currently favors the application of digital technologies in the treatment and management of CVD.
A significant shift has taken place in the US in Cardiovascular care from volume-based, fee-for-service (FFS) payment models to those centered on quality as well as patient outcomes. As a result, value-based care (VBC) payment schemes are available in a spectrum of risk and competency requirements. The transition to VBC payment structures is altering the economics of cardiology providers and putting MedTech manufacturers at risk of commercialization unless they produce unique, significant solutions. In order to encourage new financial structures and provider incentives, MedTech companies are now developing cardiovascular solutions that have clinical and financial value in addition to product performance. Therefore, in the coming years, the expedited incorporation of digital solutions presents robust growth opportunities for the regional market's growth.
The US market dominated the North America Cardiovascular Digital Solutions Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $34,667.6 Million by 2028. The Canada market is poised to grow at a CAGR of 6% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 5.1% during (2022 - 2028).
Based on Service Type, the market is segmented into Unobtrusive Testing, CVD Health Informatics, Cardiac Rehab Programs and Others. Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Care Centers and Others. Based on Deployment, the market is segmented into Cloud-Based and On-premise. Based on Components, the market is segmented into Devices and Software. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Cardiovascular Digital Solutions Market is Predict to reach $128.1 Billion by 2028, at a CAGR of 4.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Apple, Inc., General Electric Company, Koninklijke Philips N.V., Verily Life Sciences LLC (Alphabet, Inc.), iRhythm Technologies, Inc., Bardy Diagnostics, Inc. (Hill-Rom Holdings Inc) (Baxter International Inc.), eviCore Healthcare (Express Scripts Holding Company) (Cigna Corporation), AliveCor, Inc., Cardiotrack, and HeartFlow, Inc.
By Service Type
By End-use
By Deployment
By Components
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 